

Rheumatoid Arthritis (RA) Therapeutic and Drug Pipeline Review H2

Global Rheumatoid Arthritis (RA) Drugs and Companies Pipeline Review H2 2017

PUNE, INDIA, February 17, 2017
/EINPresswire.com/ -- Description

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a number of aberrant cell signaling events trigger chronic inflammation of the synovium – the soft tissue of the joint – leading to pain, joint stiffness, and eventually deformity and disability.

With the disease affecting 0.3–1.0% of the global population, the societal and economic costs of RA are substantial. The large target patient population and the relatively high annual cost of therapy have resulted in a crowded, highly lucrative market.

Treatment options have improved and diversified substantially over the past two decades, largely owing to the advent of biologics. Despite this, considerable unmet needs remain within RA. Consequently, opportunities for future drug developments remain significant, particularly for first-in-class innovation, which is the area most likely to produce substantial clinical advances.

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/822685-frontier-pharma-rheumatoid-arthritis-class-product-innovation>

Scope

Treatment options for RA have advanced over the past two decades, resulting in a crowded, competitive market landscape.

What is the pathophysiology of RA?

Which products and therapeutic strategies dominate the clinical and commercial landscapes?

What are the most significant unmet needs within the RA market?

Considerable diversification from current market trends is evident within the RA pipeline.



WISE GUY
R E P O R T S

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Which molecular targets are most prominent within the pipeline?

What proportion of pipeline products are first in class?

Which first-in-class targets are most promising?

Deal values for licensing and co-development deals vary considerably.

How many strategic consolidations have been completed in the past decade?

Which types of assets attract the largest deal values?

Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons to Buy

This report will allow you to:

Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, diagnosis, and treatment options.

Visualize the composition of the RA landscape, including key unmet needs, in order to gain a competitive understanding of gaps in the current market.

Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the RA pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.

Identify first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Executive Summary 5

2.1 A Crowded, Competitive Market, with Significant Unmet Needs Remaining 5

2.2 Early-Stage Pipeline Offers Greatest Promise for First-in-Class Innovation 5

2.3 Cytokine and Cytokine Receptors, as well as Protein Kinases, Largely Dominate First-in-Class Pipeline Products 5

3 The Case for Innovation 6

3.1 Growing Opportunities for Biologic Products 7

3.2 Diversification of Molecular Targets	7
3.3 Innovative First-in-Class Development Remains Attractive	8
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation	8
3.5 Sustained Innovation	
3.6 GBI Research Report Guidance	9
4 Clinical and Commercial Landscapes	
4.1 Disease Overview	
4.2 Disease Symptoms	
4.3 Epidemiology	
4.4 Etiology	
4.5 Pathophysiology	
4.6 Co-morbidities and Complications	
5 Assessment of Pipeline Product Innovation 17	
5.1 Rheumatoid Arthritis Pipeline by Stage of Development, Molecule Type and Molecular Target	17
5.2 Comparative Distribution of Programs between the Rheumatoid Arthritis Market and Pipeline by Therapeutic Target Family	21
5.3 First-in-Class Programs Targeting Novel Molecular Targets	21
6 Signaling Network, Disease Causation and Innovation Alignment	
6.1 Complexity of Signaling Networks in Rheumatoid Arthritis	
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration	
6.3 First-in-Class Matrix Assessment	
7 First-in-Class Target Evaluation 37	
7.1 Pipeline Programs Targeting XXX	37
8 Strategic Consolidations	
8.1 Industry-Wide First-in-Class Deals	
8.2 Licensing Deals	49
8.3 Co-development Deals	52
8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals	
9 Appendix	

...Continued

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/822685-frontier-pharma-rheumatoid-arthritis-class-product-innovation>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.